.png)
Hong Kong lives longer than almost anywhere on earth. Consistently ranked among the world's highest for life expectancy, the city has built a genuine longevity advantage — driven by decades of declining cardiovascular mortality, effective public health policy, and a dense, well-resourced private healthcare market.
But in medicine, longevity and healthspan are not the same thing.
A 2025 study examining non-communicable diseases and longevity in Hong Kong notes that while total life expectancy continues to rise, there are increasing trends in frailty and daily activity deficits among recent cohorts of older people — raising questions about whether longer life is coming at the expense of rising dependency. Hong Kong may be adding years to life. The harder question is whether it is adding life to those years.
For healthcare providers building screening programmes in this city, that distinction is not philosophical. It is the central clinical and commercial challenge of the next decade — and one that existing screening models are not fully designed to meet.
The longevity statistics tell one story. Consumer health data tells another. A Kantar survey found that 81% of individuals in Hong Kong exhibit symptoms of suboptimal health, and 77% of Hong Kong respondents in the Manulife Asia Care Survey 2025 now define health not as the absence of illness, but as the ability to live well and independently. Patients are not asking to be told whether their results are in range. They are asking what their health today means for how they will live in twenty years. Private screening providers who can answer that question are offering something categorically more valuable than those who cannot.
Government policy is moving in the same direction. The Chronic Disease Co-Care Pilot Scheme, launched in November 2023, routes subsidised diabetes and hypertension screening through private family doctors, with over 131,000 enrolled by May 2025 — approximately 40% of whom were diagnosed with prediabetes, diabetes, hypertension, or hyperlipidaemia. The government's Primary Healthcare Blueprint is explicit about the goal: shift chronic disease management into the community before patients reach the hospital system, compressing morbidity alongside longevity. The private sector is the intended vehicle.
But the structured risk assessment tools that the Hospital Authority has built for its own diabetes patients do not extend to private practice. Private family doctors managing a government-subsidised diabetes caseload through CDCC are doing so without the clinical infrastructure the public system has developed over three decades. That asymmetry — between the patients now flowing through private clinics and the tools available to manage them — is the gap this series is about.
If you want to understand what the healthspan gap looks like in clinical practice, chronic kidney disease is the sharpest case study available.
CKD does not usually arrive alone. In the vast majority of cases it develops in the shadow of another condition — most commonly diabetes. Hong Kong's Department of Health Population Health Survey 2020–22 found a diabetes prevalence of 8.5% among adults aged 15–84, rising sharply to 19% among those aged 65–84. In a rapidly ageing city, that number has significant forward momentum. More older adults. More diabetes. More CKD.
The scale of downstream risk is substantial. A multidisciplinary expert panel including nephrologists from leading Hong Kong institutions recently published a consensus review noting that diabetes is a major risk factor for CKD and that there needs to be a agreed-upon Hong Kong-specific framework for prioritising its early identification and intervention.
The scale of downstream risk is substantial. More than 40% of people with diabetes will develop CKD — and in Hong Kong, diabetes is already responsible for 49.6% of all kidney replacement therapy cases. The first consensus recommendations for CKD screening and management specifically tailored to Hong Kong clinical practice were published in December 2024, developed by a multidisciplinary expert panel of clinicians. Consensus on paper does not mean adoption. There is great opportunity for structured approaches to identifying which diabetic patients are heading toward CKD to become standard practice.
Early-stage CKD produces no symptoms. There is no pain, no obvious warning that kidney function is quietly declining. Symptoms — fatigue, swelling, changes in urination — typically appear only when the disease has progressed to stage 4 or 5, at which point the window for meaningful intervention has largely closed.
The healthspan consequences of late detection go further than the clinical. End-stage kidney disease does not only shorten life — it fundamentally redefines it. Haemodialysis requires multiple sessions per week, each lasting several hours, as a permanent, life-long commitment. It restricts travel, limits diet, constrains employment, and creates sustained dependency on clinical infrastructure. This is the measurable opposite of what Hong Kong's older population says it wants: the independence and function to do what matters to them.
The diagnostic gap is striking. A major analysis published in The Lancet found that across five high-income countries, between 64% and 96% of stage 3 CKD cases remain undiagnosed. Hong Kong's sophisticated healthcare system may perform better — but sophistication only helps if the tools interpreting screening data are designed to surface risk before it becomes irreversible disease.
The clinical consequences of missed CKD are well documented. The financial ones are less visible — because in Hong Kong, the public system absorbs most of them. A detailed study by researchers at the University of Hong Kong and partner hospitals found that hospital-based haemodialysis costs the healthcare system over HK$400,000 per patient in the first year of treatment — more than three times the annual cost of peritoneal dialysis. With the Hospital Authority subsidising public healthcare at rates of up to 97.6%, these costs accumulate almost entirely on public finances — for patients who often had detectable early-stage disease that was never acted upon. It is the fiscal logic behind the government's push toward prevention-first primary care, and behind schemes like CDCC that route chronic disease management through the private sector before patients reach the hospital system.
For a private screening provider, the consequence is different but equally direct. A patient who progresses to end-stage kidney disease enters the public hospital system and is lost to your programme entirely. The opportunity to be part of their health journey — to demonstrate the value of preventive screening at the moment it matters most — closes permanently. Prevention that intercepts the trajectory from risk to disease is not just a clinical capability. For a private provider operating in a market where patients are increasingly asking what their health today means for how they will live in twenty years, it is the product.
The good news is that many Hong Kong health screening panels already collect the relevant data. Estimated glomerular filtration rate (eGFR) appears in a significant proportion of standard packages offered by major private hospitals. KDIGO clinical practice guidelines identify both eGFR and urinary albumin-to-creatinine ratio (uACR) as the primary markers for CKD staging and risk classification; uACR — a more sensitive early marker of diabetic kidney damage — is less consistently included across standard packages in Hong Kong.
But the deeper gap is not primarily about which tests appear on the panel.
It is about what happens to the data after collection. A standard screening report presents each biomarker against its reference range in isolation. It does not synthesise a mildly elevated creatinine with a borderline HbA1c, a modestly raised blood pressure, and a family history of diabetes into a coherent risk signal. The pattern that indicates a patient is heading toward CKD — before any individual result triggers clinical concern — remains invisible in the way most results are currently presented and reviewed.
And there is a harder question still. Even for a diabetic patient whose kidney markers today look normal, the relevant clinical question for healthspan is not "do they have CKD?" It is "which of these patients will develop CKD in the next three years?" That question cannot be answered by reviewing reference ranges in isolation. It requires a fundamentally different understanding of what screening data is for — and what it should be able to tell you.
That is where the next phase of health screening in Hong Kong needs to go.
If you missed the first post in this series, start with why your health screening reports may be doing more harm than good. In the next post, we look at what it costs clinics to run health screening the manual way — and where the operational burden is heaviest.
Mesh Bio builds AI-powered health screening software for healthcare providers across Asia. To see how our platform supports earlier risk detection and smarter clinical decision-making in health screening, book a 20-minute walkthrough.
References used in this post
